JESSE GOODMAN - 14 Jun 2023 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
/s/James Basta, Attorney-In-Fact
Issuer symbol
NTLA
Transactions as of
14 Jun 2023
Transactions value $
$0
Form type
4
Filing time
16 Jun 2023, 16:28:09 UTC
Previous filing
16 Jun 2022
Next filing
21 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Award $0 +4.43K +60.69% $0.00 11.7K 14 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Award $0 +6.47K $0.00 6.47K 14 Jun 2023 Common Stock 6.47K $45.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2 This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.